Idiopathic Pulmonary Arterial Hypertension
24
4
5
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 24 trials
100.0%
+13.5% vs benchmark
8%
2 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (24)
Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled Trial
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
Hormonal, Metabolic, and Signaling Interactions in PAH
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
Empagliflozin in Pulmonary Arterial Hypertension
Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmonary Hypertension When Using Modern Strategies of Specific Therapy
StratosPHere (Non-interventional Study)
Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome
A Mobile Health Intervention in Pulmonary Arterial Hypertension
Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
The PAH Platform for Deep Phenotyping in Korean Subjects
The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects
Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
Acute Effects of Benzbromaron on the Pulmonary Circulation
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies
Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension
Beta-blockers in i-PAH
Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate